Lincoln Capital Corp lifted its holdings in Amgen, Inc. (NASDAQ:AMGN) by 3.6% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 22,248 shares of the medical research company’s stock after purchasing an additional 765 shares during the quarter. Amgen accounts for about 3.6% of Lincoln Capital Corp’s investment portfolio, making the stock its 12th biggest holding. Lincoln Capital Corp’s holdings in Amgen were worth $4,305,000 as of its most recent SEC filing.
Several other hedge funds have also bought and sold shares of the company. Parkside Financial Bank & Trust grew its holdings in shares of Amgen by 2.6% in the third quarter. Parkside Financial Bank & Trust now owns 1,883 shares of the medical research company’s stock worth $364,000 after acquiring an additional 47 shares during the period. Benjamin F. Edwards & Company Inc. grew its holdings in shares of Amgen by 4.0% in the third quarter. Benjamin F. Edwards & Company Inc. now owns 22,066 shares of the medical research company’s stock worth $4,270,000 after acquiring an additional 854 shares during the period. Taylor Hoffman Wealth Management grew its holdings in shares of Amgen by 21.5% in the third quarter. Taylor Hoffman Wealth Management now owns 1,890 shares of the medical research company’s stock worth $366,000 after acquiring an additional 334 shares during the period. Lenox Wealth Management Inc. grew its holdings in shares of Amgen by 27.0% in the third quarter. Lenox Wealth Management Inc. now owns 409 shares of the medical research company’s stock worth $79,000 after acquiring an additional 87 shares during the period. Finally, DT Investment Partners LLC grew its holdings in shares of Amgen by 4.6% in the third quarter. DT Investment Partners LLC now owns 22,562 shares of the medical research company’s stock worth $4,366,000 after acquiring an additional 994 shares during the period. Hedge funds and other institutional investors own 76.33% of the company’s stock.
NASDAQ:AMGN traded up $3.12 during mid-day trading on Friday, hitting $221.11. 2,069,900 shares of the company traded hands, compared to its average volume of 2,911,719. Amgen, Inc. has a one year low of $166.30 and a one year high of $221.25. The company has a quick ratio of 2.59, a current ratio of 2.89 and a debt-to-equity ratio of 2.54. The stock’s fifty day moving average price is $202.75 and its 200-day moving average price is $188.90. The firm has a market cap of $127.80 billion, a price-to-earnings ratio of 15.35, a price-to-earnings-growth ratio of 2.21 and a beta of 1.09.
Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Tuesday, October 29th. The medical research company reported $3.66 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.53 by $0.13. Amgen had a return on equity of 80.26% and a net margin of 34.48%. The business had revenue of $5.74 billion for the quarter, compared to the consensus estimate of $5.63 billion. During the same period in the prior year, the business posted $3.69 earnings per share. The company’s quarterly revenue was down 2.8% compared to the same quarter last year. Equities analysts predict that Amgen, Inc. will post 14.44 EPS for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Friday, December 6th. Shareholders of record on Friday, November 15th will be given a dividend of $1.45 per share. The ex-dividend date of this dividend is Thursday, November 14th. This represents a $5.80 dividend on an annualized basis and a yield of 2.62%. Amgen’s dividend payout ratio (DPR) is presently 40.28%.
In other news, Director R Sanders Williams sold 425 shares of the stock in a transaction that occurred on Wednesday, November 6th. The stock was sold at an average price of $215.45, for a total value of $91,566.25. Following the sale, the director now directly owns 5,413 shares in the company, valued at $1,166,230.85. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, Director Ronald D. Sugar sold 2,000 shares of the stock in a transaction that occurred on Wednesday, October 2nd. The stock was sold at an average price of $193.58, for a total value of $387,160.00. Following the completion of the sale, the director now owns 16,436 shares in the company, valued at $3,181,680.88. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 17,851 shares of company stock worth $3,685,674. Company insiders own 0.25% of the company’s stock.
AMGN has been the subject of several research analyst reports. Mizuho reaffirmed a “hold” rating and issued a $212.00 price objective on shares of Amgen in a report on Sunday, September 29th. Piper Jaffray Companies lifted their price objective on Amgen from $210.00 to $218.00 and gave the stock an “overweight” rating in a report on Monday, August 26th. Sanford C. Bernstein initiated coverage on Amgen in a report on Monday, October 14th. They issued an “outperform” rating for the company. Evercore ISI reaffirmed a “hold” rating on shares of Amgen in a report on Sunday, August 11th. Finally, Cantor Fitzgerald raised Amgen from a “neutral” rating to an “overweight” rating and lifted their price objective for the stock from $230.00 to $255.00 in a report on Tuesday, November 5th. Ten analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $219.56.
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells.
Featured Story: What is a Roth IRA?
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.